Q&A: PureTech CEO Daphne Zo­har talks biotech in­ter­ests on Capi­tol Hill

As the year is near­ing a close, law­mak­ers are still chip­ping away at spend­ing bills and a long to-do list of health pol­i­cy pri­or­i­ties that could come with some big changes for the biotech in­dus­try.

End­points News sat down with PureTech CEO and BIO board mem­ber Daphne Zo­har to talk about the biggest is­sues fac­ing biotech, what she urged law­mak­ers to pri­or­i­tize dur­ing re­cent meet­ings on Capi­tol Hill with BIO board mem­bers, and why she thinks biotech needs to be leg­is­lat­ed dif­fer­ent­ly than phar­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER